Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec;15(16):1973-83.
doi: 10.2217/pgs.14.153.

Genotype and risk of major bleeding during warfarin treatment

Vivian K Kawai  1 , Andrew Cunningham, Susan I Vear, Sara L Van Driest, Abimbola Oginni, Hua Xu, Min Jiang, Chun Li, Joshua C Denny, Christian Shaffer, Erica Bowton, Brian F Gage, Wayne A Ray, Dan M Roden, C Michael Stein
Affiliations

Genotype and risk of major bleeding during warfarin treatment

Vivian K Kawai et al. Pharmacogenomics. 2014 Dec.

Abstract

Aim: To determine whether genetic variants associated with warfarin dose variability were associated with increased risk of major bleeding during warfarin therapy.

Materials & methods: Using Vanderbilt's DNA biobank we compared the prevalence of CYP2C9, VKORC1 and CYP4F2 variants in 250 cases with major bleeding and 259 controls during warfarin therapy.

Results: CYP2C9*3 was the only allele that differed significantly among cases (14.2%) and controls (7.8%; p = 0.022). In the 214 (85.6%) cases with a major bleed 30 or more days after warfarin initiation, CYP2C9*3 was the only variant associated with bleeding (adjusted odds ratio: 2.05; 95% CI: 1.04, 4.04).

Conclusion: The CYP2C9*3 allele may double the risk of major bleeding among patients taking warfarin for 30 or more days.

Keywords: CYP2C9; CYP4F2; VKORC1; pharmacogenetics; risk of major bleeding; warfarin.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Algorithm used to identify cases and controls for the final analysis
†517 potential cases and 839 potential controls were reviewed to identify 277 cases and 307 controls frequency matched for age, sex, race and year of hospital admission who met the case and control definition. ‡Not genotyped because they had either opted-out or had inadequate DNA concentration for genotyping. EMR: Electronic medical record; ICD-9: International Classification of Diseases, 9th Revision, Clinical Modification.
Figure 2
Figure 2. Major bleeding risk
Genotype and risk of major bleeding (A) during warfarin therapy and (B) after 30 days of warfarin therapy. Adjusted for age, sex, race, body surface area, log[time on warfarin], VKORC1, CYP2C9*2, CYP2C9*3, CYP4F2 genotype, number of warfarin inhibitors, number of warfarin potentiators, use of antiplatelet agents and nonsteroidal anti-inflammatory drugs, previous bleeding without warfarin and atrial fibrillation and venous thromboembolism as indication for warfarin. CYP2C9*2+*3 represents the combined genotype information for CYP2C9*2 and CYP2C9*3 in an additive model (0 allele = 0, 1 allele = 1 and 2 allele = 2; e.g., *1/*1 = 0, *1/*2 = 1, *1/*3 = 1, *2/*2 = 2; *2/*3 = 2). OR: Odds ratio.
See this image and copyright information in PMC

References

    1. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5):615–621. - PMC - PubMed
    1. Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin – fourth edition. Br J Haematol. 2011;154(3):311–324. - PubMed
    1. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349(7):631–639. - PubMed
    1. Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest. 2004;126(6):1938–1945. - PubMed
    1. Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin – nature or nurture? Clin Pharmacol Ther. 2001;70(2):159–164. - PubMed

Publication types

MeSH terms